NCT03226418 2026-03-10
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
Phase 2 Completed
Clinical Trials
9 trialsNCT04231851 2026-03-06
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
University of California, Irvine
Phase 2 Active not recruiting
NCT03466450 2024-03-28
GEINOGLAS
Grupo Español de Investigación en Neurooncología
Phase 1/2 Completed
NCT03390296 2023-09-05
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04093505 2022-07-01
GnG
University Hospital Heidelberg
Phase 3 Terminated
NCT04655391 2022-06-09
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
City of Hope Medical Center
Phase 1 Withdrawn
NCT01841333 2022-01-25
PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
University of Colorado, Denver
Phase 2 Completed
NCT04051996 2021-10-15
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
Yale University
Phase 2 Terminated
NCT01842646 2021-06-14
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed